Browse > Article

Raloxifene and Lipid Profiles in Postmenopausal Women: A Systematic Review  

Yoo, Ji-Soo (Department of Clinical Nursing Science, College of Nursing, Nursing Policy Research Institute, Biobehavioral Research Center, Yonsei University)
An, Ji-Hyoun (Department of Clinical Nursing Science, College of Nursing, Yonsei University)
Kim, Doo-Ree (Department of Clinical Nursing Science, College of Nursing, Yonsei University)
Chu, Sang-Hui (Department of Clinical Nursing Science, College of Nursing, Nursing Policy Research Institute, Biobehavioral Research Center, Yonsei University)
Publication Information
Journal of Korean Biological Nursing Science / v.12, no.1, 2010 , pp. 63-72 More about this Journal
Abstract
Purpose: The purpose of this study is to assess the effects of raloxifene in prevention of cardiovascular disease in postmenopausal women. Methods: A systematic literature review was conducted. Data sources: The existing literature from 1986 to 2009 was searched electronically using the data base of Medline with the key words of hypertension, obesity, diabetes, cholesterol, lipid, myocardial infarction, coronary events with combination of raloxifene. Study selection: The criteria for inclusion in the review were 1) an randomized clinical trial (RCT), 2) postmenopausal women, 3) English or Korean language. Finally, 15 articles were included in the review. Data extraction: Findings from the studies were organized according to the results of lipid profile changes by two authors. Results: Among 15 articles, 12 studies reported the beneficial effects of raloxifene on LDL cholesterol and 9 studies on total cholesterol in the postmenopausal women. Conclusion: The consistent results on reduction of LDL cholesterol and total cholesterol in raloxifene using postmenopausal women were confirmed. However, the effect of raloxifene on other components of lipid profile and endothelial function were still remaining controversial.
Keywords
Raloxifene; Postmenopause; Women; Lipids;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Barrett-Connor, E., Ensrud, K. E., Harper, K., Mason, T. M., Sashegyi, A., Krueger, K. A., et al. (2003). Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical Therapeutics, 25, 919-930.   DOI   ScienceOn
2 Colacurci, N., Manzella, D., Fornaro, F., Carbonella, M., & Paolisso, G. (2003). Endothelial function and menopause: Effects of raloxifene administration. The Journal of Clinical Endocrinology & Metabolism, 88, 2135-2140.   DOI   ScienceOn
3 Hernandez, E., Valera, R., Alonzo, E., Bajares-Lilue, M., Carlini, R., Capriles, F., et al. (2003). Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney International, 63, 2269-2274.   DOI   ScienceOn
4 Mosca, L., Grady, D., Barrett-Connor, E., Collins, P., Wenger, N., Abramson, B. L., et al. (2009). Effect of raloxifen on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke, 40, 147- 155.   DOI   ScienceOn
5 Vogelvang, T. E., Mijatovic, V., Kenemans, P., Teerlink, T., & van der Mooren, M. J. (2004). HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertility and Sterility, 82, 1540-1549.   DOI   ScienceOn
6 Walsh, B. W., Kuller, L. H., Wild , R. A., Paul, S., Farmer, M., Lawrence, J. B., et al. (1998). Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. The Journal of the American Medical Association, 279, 1445-1451.   DOI   ScienceOn
7 Yildiz, M. F., Kumru, S., Godekmerdan, A., & Kutlu, S. (2005). Effects of raloxifene, hormone therapy, and soy isoflavone on serum highsensitive C-reactive protein in postmenopausal women. International Journal of Gynecology &Obstetrics, 90, 128-133.   DOI   ScienceOn
8 Zeng, S., Wu, Y., Zhang, Z., Yang, X., Hui, Y., Zhang, Y., et al. (2003). Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: A randomized clinical trial in Beijing. Chinese Medical Journal, 116, 1127-1133.
9 Simoncini, T., Genazzani, A. R., & Liao, J. K. (2002). Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation, 105, 1368-1373.   DOI   ScienceOn
10 Regitz-Zagrosek, V., Wintermantel, T. M., & Schubert, C. (2007). Estrogens and SERMs in coronary heart disease. Current Opinion in Pharmacology, 7, 130-139.   DOI   ScienceOn
11 Song, E. K., Yeom, J. H., Shin, H. T., Kim, S. H., Shin, W. G., & Oh, J. M. (2006). Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy. Journal of Clinical Pharmacy and Therapeutics, 31, 421-427.   DOI   ScienceOn
12 Ministry of Health and Welfare and Korea Institute for Health and Social Affairs. (2005). The Third Korea National Health and Nutrition Examination Survey. Unpublished Report.
13 Nickelsen, T., Creatsas, G., Rechberger, T., Depypere, H., Erenus, M., Quail, D., et al. (2001). Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: Results from the Euralox 1 study. Climacteric, 4, 320-331.   DOI
14 Oh, E. K., Choi, H., Lee, C. M., Cho, Y. K., Kim, B. R., Ko, J. K., et al. (2006). A comparion of the effects of raloxifene and estrogen therapy on lipid profile and bone mineral density in postmenopausal women. Journal of Korean Postmenopause, 12, 19-27.
15 Reid, I. R., Eastell, R., Fogelman, I., Adachi, J. D., Rosen, A., Netelenbos, C., et al. (2004). A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Archives of Internal Medicine, 164, 871-879.   DOI   ScienceOn
16 Kung, A. W., Chao, H. T., Huang, K. E., Need, A. G., Taechakraichana, N., Loh, F. H., et al. (2003). Efficacy and safety of raloxifene 60 milligrams/ day in postmeno-pausal Asian women. The Journal of Clinical Endocrinology &Metabolism, 88, 3130-3136.   DOI   ScienceOn
17 Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gotzsche, P. C., Ioannidis, J. P. A., et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. The British Medical Journal, 339, b2700.   DOI
18 Iwamoto, J., Sato, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2008). Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Medical Journal, 49, 119-128.   DOI   ScienceOn
19 Nanetti, L., Camilletti, A., Francucci, C. M., Vignini, A., Raffaelli, F., Mazzanti, L., et al. (2008). Role of raloxifene on platelet metabolism and plasma lipids. European Journal of Clinical Investigation, 38, 117-125.   DOI   ScienceOn
20 Hyung, H. K. & Kim, H. S. (2008). The effect of brisk walking exercise program on body composition, blood pressure, blood glucose and blood lipid for middle-aged women with obesity. Journal of Korean Biological Nursing Science, 10, 62-68.   과학기술학회마을
21 Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association, 291, 1701-1712.   DOI   ScienceOn
22 Ettinger, B., Black, D. M., Mitkma, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. The Journal of the American Medical Association, 282, 637-645.   DOI   ScienceOn
23 Grady, D., Herrington, D., Bittner, V., Blumenlhal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormones therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). The Journal of the American Medical Association, 288, 49-57.   DOI   ScienceOn
24 Griffiths, K. A., Sader, M. A., Skilton, M. R., Harmer, J. A., & Celermajer, D. S. (2003). Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. Journal of the American College of Cardiology, 42, 698-704.   DOI   ScienceOn
25 Duvernoy, C. S., Kulkarni, P. M., Dowsett, S. A., & Keech, C. A. (2005). Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: Incidence, patient characteristics, and effect of raloxifene. Menopause, 12, 444-452.   DOI   ScienceOn
26 Engin-Ustun, Y., Ustun, Y., Meydanli, M. M., & Kafkasli, A. (2006). Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: A randomized, placebo-controlled clinical trial. Gynecological Endocrinology, 22, 676-679.   DOI   ScienceOn
27 Collins, P., Mosca, L., Geiger, M. J., Grady, D., Kornitzer, M., Amewou- Atisso, M. G., et al. (2009). Effets of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for the Heart trial: Results of subgroup analyses by age and other factors. Circulation, 119, 922-930.   DOI   ScienceOn
28 Dias, A. R. Jr., Melo, R. N., Gebara, O. C., D'Amico, E. A., Nussbacher, A., Halbe, H. W., et al. (2005). Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric, 8, 63-70.   DOI   ScienceOn
29 Brussaard, H. E., Gevers, L. J., Frolich, M., Kluft, C., & Krans, H. M. (1997). Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. Diabetologia, 40, 843-849.   DOI   ScienceOn
30 Chu, S. H., Lee, M. K., Kowalski, J., Beck, J., & Schwertz, D. (2008). Effect of estrogen on ovariectomy-induced obesity in rats. Journal of Korean Biological Nursing Science, 10, 80-87.   과학기술학회마을